Breaking News Instant updates and real-time market news.

TLND

Talend

$49.40

-1.81 (-3.53%)

09:36
03/25/19
03/25
09:36
03/25/19
09:36

Talend price target raised to $62 from $50 at BTIG

BTIG analyst Edward Parker raised his price target on Talend to $62 and kept his Buy rating, saying he is turning "more comfortable" that the company is "shrugging off Big Data jitters and that demand fundamentals are much healthier than the revenue accounting would suggest." While Parker expects "transitional headwinds" to impact Talend's topline growth rate for several more quarters, he sees its "aggressive pivot towards cloud data integration" as the right strategy, adding that the company's valuation has also "recovered meaningfully".

TLND Talend
$49.40

-1.81 (-3.53%)

11/08/18
RSBL
11/08/18
DOWNGRADE
RSBL
Neutral
Talend downgraded to Neutral from Buy at Rosenblatt
Rosenblatt analyst Marshall Senk downgraded Talend to Neutral following Q3 results saying the Cloud transition weighed on results and Data Center continued to decelerate.
11/19/18
KEYB
11/19/18
NO CHANGE
Target $52
KEYB
Overweight
Talend price target lowered to $52 from $61 at KeyBanc
KeyBanc analyst Brent Bracelin lowered his price target for Talend to $52 from $61 to reflect heightened industry risk tied to on-premise data lakes migrating to the cloud. Given the risk of slowing growth next year appears fully baked into valuation, the analyst reiterates an Overweight rating on the shares.
11/20/18
BTIG
11/20/18
NO CHANGE
Target $50
BTIG
Buy
Talend price target lowered to $50 from $80 at BTIG
BTIG analyst Edward Parker lowered his price target on Talend to $50 after its Q3 earnings miss, below-consensus Q4 guidance, and the company's disappointing FY19 outlook of growth in the "low 20's" vs its prior expectations of at least 27%. The analyst contends that better messaging and transparency are needed from the management, but also attributes the reset to the company's "revenue recognition optics and faster than expected ratable transition, rather than a change in aggregate demand for data integration products." Parker keeps his Buy rating on Talend, adding that "consensus is appropriately optimistic" regarding the company's focus on the cloud integration market.
01/08/19
KEYB
01/08/19
NO CHANGE
KEYB
Microsoft, Salesforce among top Software stocks to own in 2019, says KeyBanc
KeyBanc analyst Brent Bracelin notes that despite challenging market conditions during Q4, the 45 software applications in his coverage universe outperformed the broader market by a wide margin. While industry conditions for application software appear more volatile entering 2019, the analyst sees a favorable backdrop for modern cloud-based applications with recurring subscription-based revenue models and continues to favor growth over value. His top software application stocks to own for 2019 include Microsoft (MSFT), Synopsys (SNPS), PTC (PTC), RealPage (RP), Talend (TLND), Salesforce (CRM), Shopify (SHOP), Twilio (TWLO), Avalara (AVLR).

TODAY'S FREE FLY STORIES

AQST

Aquestive Therapeutics

$7.89

-0.13 (-1.62%)

15:25
12/09/19
12/09
15:25
12/09/19
15:25
Conference/Events
Aquestive Therapeutics holds analyst & investor event w/conference call hookup »

Management and Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

PTLA

Portola Pharmaceuticals

$28.48

-0.74 (-2.53%)

15:24
12/09/19
12/09
15:24
12/09/19
15:24
Hot Stocks
Portola presents new interim Phase 2a data from study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$19.72

10.045 (103.88%)

15:21
12/09/19
12/09
15:21
12/09/19
15:21
Downgrade
ArQule rating change  »

ArQule downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

TOL

Toll Brothers

$41.50

0.62 (1.52%)

15:19
12/09/19
12/09
15:19
12/09/19
15:19
Options
Toll Brothers options imply 8.6% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/09/19
12/09
15:17
12/09/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/09/19
12/09
15:16
12/09/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$33.53

-0.06 (-0.18%)

15:15
12/09/19
12/09
15:15
12/09/19
15:15
Options
Dish put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$9.87

0.19 (1.96%)

15:09
12/09/19
12/09
15:09
12/09/19
15:09
Hot Stocks
MacroGenics announces updated results from Phase 1/2 study of flotetuzumab »

MacroGenics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MDB

MongoDB

$131.13

-0.09 (-0.07%)

15:04
12/09/19
12/09
15:04
12/09/19
15:04
Options
MongoDB options imply 14.8% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 18

    Dec

IMGN

ImmunoGen

$4.06

0.195 (5.05%)

15:03
12/09/19
12/09
15:03
12/09/19
15:03
Hot Stocks
ImmunoGen presents updated findings from Phase 1 study of IMGN632 at ASH meeting »

ImmunoGen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/09/19
12/09
15:00
12/09/19
15:00
General news
U.S.-China trade/tariff uncertainty is still present »

U.S.-China trade/tariff…

NVS

Novartis

$92.68

0.6 (0.65%)

14:53
12/09/19
12/09
14:53
12/09/19
14:53
Hot Stocks
Novartis says Kymriah demonstrates consistent efficacy, safety outcomes »

Novartis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GILD

Gilead

$67.11

0.02 (0.03%)

14:51
12/09/19
12/09
14:51
12/09/19
14:51
Hot Stocks
Gilead's Kite says results ZUMA-2 trial support regulatory filings »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMDA

Gamida Cell

$5.10

0.01 (0.20%)

14:49
12/09/19
12/09
14:49
12/09/19
14:49
Hot Stocks
Gamida Cell announces results from Phase 1 clinical study of GDA-201 »

Gamida Cell announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$25.05

0.92 (3.81%)

14:49
12/09/19
12/09
14:49
12/09/19
14:49
Options
Stitch Fix options imply 24.0% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

GILD

Gilead

$67.08

-0.01 (-0.01%)

14:47
12/09/19
12/09
14:47
12/09/19
14:47
Hot Stocks
Gilead's Kite announces findings from ongoing post-marketing study of Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$17.55

-0.34 (-1.90%)

14:45
12/09/19
12/09
14:45
12/09/19
14:45
Options
Nuance call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GS

Goldman Sachs

$222.17

-2.4 (-1.07%)

, SFTBF

SoftBank

$0.00

(0.00%)

14:41
12/09/19
12/09
14:41
12/09/19
14:41
Periodicals
SoftBank taps Goldman for $1.75B financing to help revive WeWork, Bloomberg says »

SoftBank (SFTBF) has…

GS

Goldman Sachs

$222.17

-2.4 (-1.07%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

  • 26

    Feb

CBL

CBL & Associates

$1.12

-0.025 (-2.18%)

14:36
12/09/19
12/09
14:36
12/09/19
14:36
Hot Stocks
CBL & Associates closes sale of interest in the Outlet Shoppes at Atlanta »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

14:25
12/09/19
12/09
14:25
12/09/19
14:25
Options
Berkshire Hathaway call volume above normal and directionally bullish »

Bullish option flow…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/09/19
12/09
14:17
12/09/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/09/19
12/09
14:16
12/09/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
12/09/19
12/09
14:15
12/09/19
14:15
General news
Treasury Action: yields are little changed »

Treasury Action: yields…

VWAGY

Volkswagen

$0.00

(0.00%)

14:08
12/09/19
12/09
14:08
12/09/19
14:08
Hot Stocks
Canada agency says VW charged with federal environmental law offences »

According to Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$88.77

-0.07 (-0.08%)

, ARQL

ArQule

$19.70

10.03 (103.72%)

14:07
12/09/19
12/09
14:07
12/09/19
14:07
Downgrade
Merck, ArQule rating change  »

ArQule downgraded to…

MRK

Merck

$88.77

-0.07 (-0.08%)

ARQL

ArQule

$19.70

10.03 (103.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.